254 related articles for article (PubMed ID: 23551210)
1. A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation.
Nakasone H; Kanda J; Yano S; Atsuta Y; Ago H; Fukuda T; Kakihana K; Adachi T; Yujiri T; Taniguchi S; Taguchi J; Morishima Y; Nagamura T; Sakamaki H; Mori T; Murata M;
Transpl Int; 2013 Jun; 26(6):631-9. PubMed ID: 23551210
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cell transplantation.
Mo XD; Xu LP; Liu DH; Zhang XH; Chen H; Chen YH; Han W; Wang Y; Wang FR; Wang JZ; Liu KY; Huang XJ
Chin Med J (Engl); 2013 Jul; 126(13):2489-94. PubMed ID: 23823823
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Gazourian L; Rogers AJ; Ibanga R; Weinhouse GL; Pinto-Plata V; Ritz J; Soiffer RJ; Antin JH; Washko GR; Baron RM; Ho VT
Am J Hematol; 2014 Apr; 89(4):404-9. PubMed ID: 24375545
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of serum surfactant protein D level prior to transplant for the development of bronchiolitis obliterans syndrome and idiopathic pneumonia syndrome following allogeneic hematopoietic stem cell transplantation.
Nakane T; Nakamae H; Kamoi H; Koh H; Takeoka Y; Sakamoto E; Kanashima H; Nakamae M; Ohta K; Terada Y; Koh KR; Yamane T; Hino M
Bone Marrow Transplant; 2008 Jul; 42(1):43-9. PubMed ID: 18347569
[TBL] [Abstract][Full Text] [Related]
5. Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation.
Duque-Afonso J; Ihorst G; Wäsch R; Bertz H; Müller-Quernheim J; Finke J; Prasse A; Marks R
Bone Marrow Transplant; 2013 Aug; 48(8):1098-103. PubMed ID: 23376822
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation.
Cheng GS; Edelman JD; Madtes DK; Martin PJ; Flowers ME
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1169-75. PubMed ID: 24727334
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
[TBL] [Abstract][Full Text] [Related]
8. Risk Factor and Clinical Outcome of Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
Rhee CK; Ha JH; Yoon JH; Cho BS; Min WS; Yoon HK; Lee JW
Yonsei Med J; 2016 Mar; 57(2):365-72. PubMed ID: 26847288
[TBL] [Abstract][Full Text] [Related]
9. Serum Krebs Von Den Lungen-6 as a Biomarker for Early Detection of Bronchiolitis Obliterans Syndrome in Children Undergoing Allogeneic Stem Cell Transplantation.
Gassas A; Schechter T; Krueger J; Craig-Barnes H; Sung L; Ali M; Dell S; Egeler RM; Zaidman I; Palaniyar N
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1524-8. PubMed ID: 25963919
[TBL] [Abstract][Full Text] [Related]
10. Value of Screening Spirometry for Early Diagnosis of Bronchiolitis Obliterans Syndrome in Children After Allogeneic Hematopoietic Stem Cell Transplantation.
Yoon JS; Chun YH; Lee JW; Chung NG; Cho B
J Pediatr Hematol Oncol; 2015 Nov; 37(8):e462-7. PubMed ID: 26334431
[TBL] [Abstract][Full Text] [Related]
11. Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning.
Watz E; Remberger M; Ringden O; Lundahl J; Ljungman P; Mattsson J; Wikman A; Uhlin M
Biol Blood Marrow Transplant; 2014 Feb; 20(2):264-71. PubMed ID: 24274982
[TBL] [Abstract][Full Text] [Related]
12. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation.
Au BK; Au MA; Chien JW
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1072-8. PubMed ID: 21126596
[TBL] [Abstract][Full Text] [Related]
13. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
14. Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
Sengsayadeth SM; Srivastava S; Jagasia M; Savani BN
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1479-87. PubMed ID: 22449611
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung.
Abedin S; Yanik GA; Braun T; Pawarode A; Magenau J; Goldstein SC; Levine JE; Kitko CL; Couriel DR
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1127-31. PubMed ID: 25687798
[TBL] [Abstract][Full Text] [Related]
16. Lower incidence of Bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning.
Yoshihara S; Tateishi U; Ando T; Kunitoh H; Suyama H; Onishi Y; Tanosaki R; Mineishi S
Bone Marrow Transplant; 2005 Jun; 35(12):1195-200. PubMed ID: 15852024
[TBL] [Abstract][Full Text] [Related]
17. Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight--new perspectives?
Ditschkowski M; Elmaagacli AH; Koldehoff M; Gromke T; Trenschel R; Beelen DW
Bone Marrow Transplant; 2013 Sep; 48(9):1224-9. PubMed ID: 23435515
[TBL] [Abstract][Full Text] [Related]
18. Early outcomes of lung transplantation for bronchiolitis obliterans syndrome after allogeneic haematopoietic stem cell transplantation: a single-centre experience.
Jung HS; Lee JG; Yu WS; Lee CY; Haam SJ; Paik HC
Interact Cardiovasc Thorac Surg; 2016 Dec; 23(6):914-918. PubMed ID: 27481680
[TBL] [Abstract][Full Text] [Related]
19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
20. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
Nakamae H; Yamane T; Hasegawa T; Nakamae M; Terada Y; Hagihara K; Ohta K; Hino M
Am J Hematol; 2006 Jul; 81(7):525-31. PubMed ID: 16755559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
